focus -WSS

focus

author：focus 2025-09-14 21:54:55 - browse：568

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： FDA has safety concerns on CRISPR

knowledge

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Democratic lawmaker calls for 'well

Biden will tout long

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

entertainment

focus

hotspot

Jerome Adams on the need for new antivirals for Covid

Why Sanofi got shellacked over its spinoff

Activists slam private health insurers over coverage restrictions

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

DIEP, the 'gold standard' of breast reconstruction, is under threat

Paying for Covid pills will soon shift to insurers

Walensky prepares to leave CDC — and Congress — behind

The pink breast cancer awareness ribbon needs a redesign

Peter Hotez and the public health issue of online harassment

Medtronic CEO on promising devices for diabetes, hypertension

leisure time

Illinois to ban advertising for guns allegedly marketed to kids and militants

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Democratic lawmaker calls for 'well

Mississippi candidates for statewide offices square off in party primaries

At least 12 people were injured in a blast at a port in northwest Turkey

focus

hotspot

knowledge

hotspot